文献速递前列腺癌

活检初治前列腺中mpMRI假阳性表型是否不同于显著癌相关病灶:PROMIS研究启示

False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS.
PubMed 文献 · Eur Urol · 2020-10-10

PROMIS研究纳入235例活检初治、PSA升高疑似前列腺癌男性,行mpMRI后以5mm经会阴模板穿刺活检为参考标准,比较有无显著癌者的mpMRI病灶特征。结果显示显著癌者更多见≥2个病灶、指数病灶体积更大、弥散受限更明显且Likert评分更高;在Likert 3指数病灶者中,log2PSA密度和病灶ADC可预测显著癌。

要点

  • 显著癌者更常见≥2个mpMRI病灶(67% vs 37%)。
  • 显著癌者指数病灶更大、更显眼且弥散受限更明显。
  • Likert 3指数病灶者中,PSA密度和ADC可预测显著癌。

核心结论

  • 活检初治男性中显著癌相关mpMRI病灶具有临床-影像学差异,无显著癌前列腺也可见类似病灶。
  • MRI计算的PSA密度和ADC可在不确定MRI表型者中预测显著癌。

研究设计与样本

  • PROMIS研究纳入235例活检初治、PSA升高疑似前列腺癌男性,行mpMRI后接受联合穿刺活检,以5mm经会阴模板穿刺活检为参考标准。
  • 178例存在指数和/或附加病灶的参与者按活检结果分为无癌、不显著癌、定义2显著癌和定义1显著癌四组进行比较。

主要发现

  • 显著癌者中≥2个病灶的比例高于无显著癌者(67% vs 37%;p<0.001)。
  • 显著癌者指数病灶平均体积更大(0.68 vs 0.50 ml;p<0.001)。
  • 显著癌者指数病灶Likert 4-5比例更高(79% vs 22%;p<0.001)。
  • 显著癌者指数病灶平均ADC更低(0.73 vs 0.86;p<0.001)。
  • 在Likert 3指数病灶者中,log2PSA密度和指数病灶ADC预测定义1/2显著癌的平均交叉验证AUC为0.77(95%CI 0.67-0.87)。

关键数值与推荐

  • 定义2显著癌:Gleason≥3+4任意长度和/或最大癌核心长度≥4mm任意分级。
  • 定义1显著癌:Gleason≥4+3任意长度和/或最大癌核心长度≥6mm任意分级。
  • Likert 3指数病灶者中,log2PSA密度和指数病灶ADC为定义1/2显著癌的显著预测因子(平均交叉验证AUC 0.77,95%CI 0.67-0.87)。

临床怎么用

  • 对mpMRI不确定病灶(如Likert 3),可结合PSA密度和ADC评估显著癌风险。
  • 认识假阳性病灶的影像特征有助于减少不必要的穿刺。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: False positive multiparametric magnetic resonance imaging (mpMRI) phenotypes prompt unnecessary biopsies. The Prostate MRI Imaging Study (PROMIS) provides a unique opportunity to explore such phenotypes in biopsy-naïve men with raised prostate-specific antigen (PSA) and suspected cancer. OBJECTIVE: To compare mpMRI lesions in men with/without significant cancer on transperineal mapping biopsy (TPM). DESIGN, SETTING, AND PARTICIPANTS: PROMIS participants (n=235) underwent mpMRI followed by a combined biopsy procedure at University College London Hospital, including 5-mm TPM as the reference standard. Patients were divided into four mutually exclusive groups according to TPM findings: (1) no cancer, (2) insignificant cancer, (3) definition 2 significant cancer (Gleason ≥3+4 of any length and/or maximum cancer core length ≥4mm of any grade), and (4) definition 1 significant cancer (Gleason ≥4+3 of any length and/or maximum cancer core length ≥6mm of any grade). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Index and/or additional lesions present in 178 participants were compared between TPM groups in terms of number, conspicuity, volume, location, and radiological characteristics. RESULTS AND LIMITATIONS: Most lesions were located in the peripheral zone. More men with significant cancer had two or more lesions than those without significant disease (67% vs 37%; p< 0.001). In the former group, index lesions were larger (mean volume 0.68 vs 0.50 ml; p< 0.001, Wilcoxon test), more conspicuous (Likert 4-5: 79% vs 22%; p< 0.001), and diffusion restricted (mean apparent diffusion coefficient [ADC]: 0.73 vs 0.86; p< 0.001, Wilcoxon test). In men with Likert 3 index lesions, log2PSA density and index lesion ADC were significant predictors of definition 1/2 disease in a logistic regression model (mean cross-validated area under the receiver-operator characteristic curve: 0.77 [95% confidence interval: 0.67-0.87]). CONCLUSIONS: Significant cancer-associated MRI lesions in biopsy-naïve men have clinical-radiological differences, with lesions seen in prostates without significant disease. MRI-calculated PSA density and ADC could predict significant cancer in those with indeterminate MRI phenotypes. PATIENT SUMMARY: Magnetic resonance imaging (MRI) lesions that mimic prostate cancer but are, in fact, benign prompt unnecessary biopsies in thousands of men with raised prostate-specific antigen. In this study we found that, on closer look, such false positive lesions have different features from cancerous ones. This means that doctors could potentially develop better tools to identify cancer on MRI and spare some patients from unnecessary biopsies.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Stavrinides V, Syer T, Hu Y, et al. False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS. Eur Urol. 2020. PMID: 33051065. doi:10.1016/j.eururo.2020.09.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。